Comparative Pharmacology
Head-to-head clinical analysis: HUMALOG versus MERILOG SOLOSTAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HUMALOG versus MERILOG SOLOSTAR.
HUMALOG vs MERILOG SOLOSTAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin lispro is a rapid-acting insulin analog that lowers blood glucose by binding to insulin receptors on skeletal muscle and adipocytes, leading to increased glucose uptake and reduced hepatic glucose production.
Insulin glargine is a recombinant human insulin analog that exhibits prolonged duration of action due to slow subcutaneous absorption. It binds to insulin receptors, activating downstream signaling pathways involved in glucose uptake, glycogen synthesis, and lipogenesis.
Subcutaneous injection: 0.2-1.0 units/kg/day divided into 3 or more doses, given within 15 minutes before or immediately after a meal. Typical total daily dose range 0.5-1.0 units/kg/day.
0.5 mg subcutaneously once a day.
None Documented
None Documented
Subcutaneous: 0.5-1.0 hour (insulin lispro); longer with renal impairment (up to 1.5-3 hours).
Terminal half-life is about 24 hours (range 18–30 hours), allowing once-daily dosing.
Renal: 60-80% as unchanged drug; biliary/fecal: minor (<10%).
Approximately 80% of the dose is excreted renally as unchanged drug, with 20% eliminated via bile/feces.
Category C
Category C
Insulin
Insulin